Prelude Therapeutics Shares Surge on Analyst Optimism and Upcoming Earnings

Prelude Therapeutics Inc shares are demonstrating remarkable upward momentum, driven by two key factors: a substantial increase in analyst price targets and growing anticipation for next week’s quarterly financial results.

Market participants are looking ahead to next week when Prelude Therapeutics is scheduled to release its third-quarter 2025 financial performance. The company is expected to announce results on Wednesday, followed by a conference call on Friday at 11:30 AM Eastern Time.

Financial analysts project a loss of $0.35 per share for the recently completed quarter. Notably, this forecast has improved significantly over the past month, narrowing from an expected loss of $0.41 to the current $0.35 projection—representing a 14.63% positive revision. The company Read more...